Comprehensive analysis of the prognostic value and biological function of TDG in hepatocellular carcinoma

References

• Hatzaras I, Bischof DA, Fahy B, et al. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):758–766.
   PubMed Web of Science ®Google Scholar
• Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–137.
   PubMed Web of Science ®Google Scholar
• Tang KY, Du SL, Wang QL, et al. Traditional Chinese medicine targeting cancer stem cells as an alternative treatment for hepatocellular carcinoma. J Integr Med. 2020;18(3):196–202.
   PubMedGoogle Scholar
• Zhao HT, Meng YB, Zhai XF, et al. Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: a prospective multicenter cohort study. J Integr Med. 2020;18(4):319–325.
   PubMedGoogle Scholar
• Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci. 2018;22(12):3855–3864.
   PubMed Web of Science ®Google Scholar
• Stoletov K, Beatty PH, Lewis JD. Novel therapeutic targets for cancer metastasis. Expert Rev Anticancer Ther. 2020;20(2):97–109.
   PubMed Web of Science ®Google Scholar
• Kang GJ, Park JH, Kim HJ, et al. PRR16/Largen induces epithelial-mesenchymal transition through the interaction with ABI2 leading to the activation of ABL1 kinase. Biomol Ther. 2020;30(4):340–347.
   Web of Science ®Google Scholar
• Edwards JR, Yarychkivska O, Boulard M, et al. DNA methylation and DNA methyltransferases. Epigenetics Chromatin. 2017;10(1):23.
   PubMedGoogle Scholar
• Wu X, Zhang Y. TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet. 2017;18(9):517–534.
   PubMed Web of Science ®Google Scholar
• Greenberg MVC, Bourc’his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20(10):590–607.
   PubMed Web of Science ®Google Scholar
• Bochtler M, Kolano A, Xu GL. DNA demethylation pathways: additional players and regulators. BioEssays. 2017;39(1):1–13.
   PubMed Web of Science ®Google Scholar
• Onabote O, Hassan HM, Isovic M, et al. The role of thymine DNA glycosylase in transcription, active DNA demethylation, and cancer. Cancers (Basel). 2022;14(3):765.
   PubMed Web of Science ®Google Scholar
• Wu H, Qiu J, Wu Z, et al. MiR-27a-3p binds to TET1 mediated DNA demethylation of ADCY6 regulates breast cancer progression via epithelial-mesenchymal transition. Front Oncol. 2022;12:957511.
   PubMedGoogle Scholar
• Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020;37(4):530–542.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Messina M, Foà R. BCR/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat? Cancer. 2019;125(2):194–204.
   PubMed Web of Science ®Google Scholar
• Massimino M, Stella S, Tirrò E, et al. ABL1-directed inhibitors for cml: efficacy, resistance and future perspectives. Anticancer Res. 2020; 40(5):2457–2465.
   Google Scholar
• Luo J, Zheng H, Wang S, et al. ABL1 and Cofilin1 promote T-cell acute lymphoblastic leukemia cell migration. Acta Biochim Biophys Sin (Shanghai). 2021;53(10):1321–1332.
   PubMed Web of Science ®Google Scholar
• Wang F, Hou W, Chitsike L, et al. ABL1, overexpressed in hepatocellular carcinomas, regulates expression of notch1 and promotes development of liver tumors in mice. Gastroenterology. 2020;159(1):289–305.
   PubMed Web of Science ®Google Scholar
• Behzad MM, Shahrabi S, Jaseb K, et al. Aberrant DNA methylation in chronic myeloid leukemia: cell fate control, prognosis, and therapeutic response. Biochem Genet. 2018;56(3):149–175.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao J, Zhu YN, et al. C1222C deletion in exon 8 of ABL1 is involved in carcinogenesis and cell cycle control of colorectal cancer through IRS1/PI3K/Akt pathway. Front Oncol. 2020;10:1385.
   PubMed Web of Science ®Google Scholar
• Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502(7472):472–479.
   PubMed Web of Science ®Google Scholar
• Yan JB, Lai CC, Jhu JW, et al. Insulin and metformin control cell proliferation by regulating TDG-Mediated DNA demethylation in liver and breast cancer cells. Mol Ther Oncolytics. 2020;18:282–294.
   PubMed Web of Science ®Google Scholar
• Miao J, Zhao C, Tang K, et al. TDG suppresses the migration and invasion of human colon cancer cells via the DNMT3A/TIMP2 axis. Int J Biol Sci. 2022;18(6):2527–2539.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Iwai S, O’Connor TR, et al. Human thymine DNA glycosylase (TDG) and methyl-CpG-binding protein 4 (MBD4) excise thymine glycol (Tg) from a Tg: g mispair. Nucleic Acids Res. 2003;31(18):5399–5404.
   PubMed Web of Science ®Google Scholar
• Deckard CE, Banerjee DR, Sczepanski JT. Chromatin structure and the pioneering transcription factor FOXA1 regulate TDG-Mediated removal of 5-formylcytosine from DNA. J Am Chem Soc. 2019;141(36):14110–14114.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, et al. Emt: 2016. Cell. 2016;166(1):21–45.
   PubMed Web of Science ®Google Scholar
• Ye X, Weinberg RA. Epithelial–mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25(11):675–686.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29(3):212–226.
   PubMed Web of Science ®Google Scholar
• De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13(2):97–110.
   PubMed Web of Science ®Google Scholar
• Xiao S, Chang RM, Yang MY, et al. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology. 2016;63(4):1256–1271.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yang YD, Fu L, et al. CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma. Oncotarget. 2014;5(17):7663–7676.
   PubMedGoogle Scholar
• Dong T, Zhang Y, Chen Y, et al. FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition. Oncotarget. 2017;8(1):1703–1713.
   PubMedGoogle Scholar
• Liu F, Kong X, Lv L, et al. TGF-beta1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. Cancer Lett. 2015;359(2):288–298.
   PubMed Web of Science ®Google Scholar
• Ma S, Meng Z, Chen R. The hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88:577–604.
   PubMed Web of Science ®Google Scholar
• Moya IM, Halder G. Hippo–yap/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2019;20(4):211–226.
   PubMed Web of Science ®Google Scholar
• Zheng Y. The Hippo Signaling Pathway in Development and Disease. Dev Cell. 2019;50(3):264–282.
   PubMed Web of Science ®Google Scholar
• Dey A, Varelas X. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020;19(7):480–494.
   PubMed Web of Science ®Google Scholar
• da Costa NM, Hautefeuille A, Cros MP, et al. Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle. 2012;11(24):4570–4578.
   PubMed Web of Science ®Google Scholar
• Cheng T, Xu M, Qin B, et al. lncRNA H19 contributes to oxidative damage repair in the early age-related cataract by regulating miR-29a/TDG axis. J Cell Mol Med. 2019;23(9):6131–6139.
   PubMed Web of Science ®Google Scholar